Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Eribulin Mesylate in Locally Advanced or Metastatic Breast Cancer
NCT03583944Phase 4Completed
- Sponsor
- Eisai Co., Ltd.
- Start
- Mar 2018
- Primary completion
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of eribulin in breast cancer, sponsored by Eisai Co., Ltd.. Started Mar 2018; status: completed.
02
Drugs
eribulin
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT03583944.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03583944.